Key Details
Annual ROE
-110.96%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 28, 2023Recent annual earnings:
Mar 28, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with AYLA included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Ayala Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Ayala Pharmaceuticals?
- What is the ticker symbol for Ayala Pharmaceuticals?
- Does Ayala Pharmaceuticals pay dividends?
- What sector is Ayala Pharmaceuticals in?
- What industry is Ayala Pharmaceuticals in?
- What country is Ayala Pharmaceuticals based in?
- When did Ayala Pharmaceuticals go public?
- Is Ayala Pharmaceuticals in the S&P 500?
- Is Ayala Pharmaceuticals in the NASDAQ 100?
- Is Ayala Pharmaceuticals in the Dow Jones?
- When was Ayala Pharmaceuticals's last earnings report?
- When does Ayala Pharmaceuticals report earnings?
What is the primary business of Ayala Pharmaceuticals?
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
What is the ticker symbol for Ayala Pharmaceuticals?
The ticker symbol for Ayala Pharmaceuticals is NASDAQ:AYLA
Does Ayala Pharmaceuticals pay dividends?
No, Ayala Pharmaceuticals does not pay dividends
What sector is Ayala Pharmaceuticals in?
Ayala Pharmaceuticals is in the Healthcare sector
What industry is Ayala Pharmaceuticals in?
Ayala Pharmaceuticals is in the Biotechnology industry
What country is Ayala Pharmaceuticals based in?
Ayala Pharmaceuticals is headquartered in Israel
When did Ayala Pharmaceuticals go public?
Ayala Pharmaceuticals's initial public offering (IPO) was on 08 May 2020
Is Ayala Pharmaceuticals in the S&P 500?
No, Ayala Pharmaceuticals is not included in the S&P 500 index
Is Ayala Pharmaceuticals in the NASDAQ 100?
No, Ayala Pharmaceuticals is not included in the NASDAQ 100 index
Is Ayala Pharmaceuticals in the Dow Jones?
No, Ayala Pharmaceuticals is not included in the Dow Jones index
When was Ayala Pharmaceuticals's last earnings report?
Ayala Pharmaceuticals's most recent earnings report was on 28 March 2023
When does Ayala Pharmaceuticals report earnings?
The date for Ayala Pharmaceuticals's next earnings report has not been announced yet